Inactive Instrument

Highlights Oxford Immunotec Global PLC

Equities

OXFD

GB00BGFBB958

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Oxford Immunotec Announces Use of T-SPOT®Discovery SARS-CoV-2 Kit	29/04/21	CI
PerkinElmer (UK) Holdings Limited completed the acquisition of Oxford Immunotec Global PLC.	07/03/21	CI
Oxford Immunotec Global PLC's Equity Buyback announced on January 7, 2019, has expired.	07/03/21	CI
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection	04/03/21	CI
Oxford Immunotec Global : Plans to Market T Cell Immune Response Measurement Kit to COVID-19 in South Korea	08/02/21	MT
Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea	08/02/21	CI
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-Cov-2 Kit and Include New Panel to Detect T Cells Reactive to Endemic Coronaviruses	04/02/21	CI
Oxford Immunotec Global : Teams With Valneva on COVID-19 Vaccine Candidate Testing	13/01/21	MT
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study	13/01/21	CI
PerkinElmer : to Acquire Oxford Immunotec for $591 Million	07/01/21	MT
PerkinElmer (UK) Holdings Limited entered into an agreement to acquire Oxford Immunotec Global PLC (NasdaqGM:OXFD for approximately $560 million.	06/01/21	CI
Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit	10/12/20	CI
Oxford Immunotec Global PLC Signs Exclusive Distributor Agreement with Riken Genesis, to Market the T-SPOT Discovery SARS-CoV-2 Kit for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection in Japan	02/12/20	CI
Oxford Immunotec Global : Study Shows Protection T Cells Offer From COVID-19 in UK Keyworkers	10/11/20	MT
Oxford Immunotec Global PLC Announces Release of Data from a Prospective Cohort Study	10/11/20	CI
Oxford Immunotec Global : Seeks FDA Approval for Tuberculosis Test Kit	05/11/20	MT
Oxford Immunotec Files Submission to Food and Drug Administration for the T-Cell Select Reagent Kit	05/11/20	CI
Tranche Update on Oxford Immunotec Global PLC's Equity Buyback Plan announced on January 7, 2019.	03/11/20	CI
Oxford Immunotec Global : Earnings Flash (OXFD) OXFORD IMMUNOTEC GLOBAL Posts Q3 Revenue $19.4M, vs. Street Est of $18.7M	03/11/20	MT
Oxford Immunotec Global PLC Provides Revenue Guidance for the Fourth Quarter of 2020	03/11/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oxford Immunotec Global PLC

Equities

OXFD

GB00BGFBB958

Highlights

Filters